Sector News

Japan’s Daiichi completely exits Sun Pharma

April 21, 2015
Life sciences
Japanese drug maker Daiichi Sankyo has sold its entire holding in Sun Pharmaceutical Industries for an estimated Rs 20,420 crore, which it received following the merger of Ranbaxy into the Indian pharma major. 
 
In a statement today, Daiichi said: “The sale of Sun Pharma shares has been completed.” 
 
The company further said it has sold its entire holding of 21,49,69,058 shares in Sun Pharmaceutical. At the average share price of about Rs 950, the value of its shares would be Rs 20,420 crore. 
 
Yesterday, Daiichi Sankyo Company Ltd had announced its decision to sell “the entire or part of its holdings of Sun Pharmaceutical shares…” 
 
It further said: “Daiichi Sankyo will make an announcement concerning the effect of any gain or loss on the sale of Sun Pharma shares when results of operations for the fiscal year ending in March 2015 are announced.” 
 
On Monday, Daiichi Sankyo said its board had approved selling a part or entire 9 per cent holding in Sun Pharma. 
 
Daiichi got around 9 per cent stake in Sun Pharma following the merger of Ranbaxy with the Indian pharma major. 
 
“The board of directors of Daiichi Sankyo Company Ltd approved a resolution on April 20 to sell entire or part of its holding of Sun Pharmaceutical Industries Ltd shares,” the Japanese firm said in a statement. 
 
Last month, Sun Pharma had announced completion of merger of Ranbaxy with itself, almost a year after announcing the USD 4-billion deal. 
 
As part of the deal, Ranbaxy shareholders were to receive 0.8 Sun Pharma shares for every Ranbaxy share they held. 
 
Daiichi Sankyo, which had acquired a majority stake in Ranbaxy in 2008 for around Rs 22,000 crore, held 63.4 per cent in the Gurgaon-based firm at the time of the merger. 
 
“From the perspective of the improvement of corporate value, Daiichi Sankyo has performed a review of the Sun Pharma shares and reached a conclusion to sell the shares entirely or partially,” it said. 
 
The merger with Ranbaxy has fortified Sun Pharma’s position as the world’s fifth largest specialty generic pharma firm and the top-ranking domestic one with a significant lead in the market share.
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach